Top Biotech Companies in Singapore (110)
STEMCELL Technologies is a Canadian biotechnology company that helps power leading-edge life science research around the world. Driven by our love of science and passion for quality, we are Scientists Helping Scientists—standing by our customers to provide the outstanding products, technical support, and training they need to advance their research. Scientists performing stem cell, immunology, cancer, regenerative medicine, and cellular...
Analytical scientists and clinical researchers worldwide rely on Agilent to help fulfill their most complex laboratory demands. Our instruments, software, services and consumables address the full range of scientific and laboratory management needs—so our customers can do what they do best: improve the world around us. Whether a laboratory is engaged in environmental testing, academic research, medical diagnostics, pharmaceuticals, petrochemicals or...
Agilent Technologies's Top Stability & Growth Strengths
Strong Market Position & Advantage: Industry and company materials consistently place Agilent among the top global players in analytical instrumentation—especially in chromatography and mass spectrometry—and as a frequent short‑list vendor for regulated and R&D labs. Recognition such as Instrument Business Outlook’s “Company of the Year” supports this standing.
Diversified Revenue Streams: The portfolio spans instruments, software/informatics, consumables, and services (Agilent CrossLab), with end‑to‑end workflows and specialty CDMO contributions providing multiple revenue levers. This breadth increases switching costs and drives recurring revenue that helps balance capital‑equipment cycles.
Resilient & Sustainable Growth: After a FY2024 decline, revenue returned to growth in FY2025 and continued in Q1 FY2026, with guidance pointing to mid‑single‑digit core growth and margin expansion. CrossLab’s steady growth and an instrument replacement cycle are cited as continuing supports.
Nuevocor is a new biotech start-up in Singapore striving to develop gene therapies for genetic cardiomyopathies. It will leverage a deep understanding of cardiac cell biology, as well as a technology platform encompassing novel gene therapy vectors and proteomics-based target discovery
Hoosier Cancer Research Network (HCRN) is an independent nonprofit contract research organization specializing in early-phase, multi-center, investigator-initiated oncology clinical trials, with a mission to advance cancer research, education, and patient advocacy.
Founded in 1996, PSC Biotech Corporation was created with the vision of providing life science companies unmatched support. To date, PSC Biotech Corporation now serves 1000 clients in more than 35 countries worldwide through professional services consulting, cloud-based software solutions, pharmaceuticals contract manufacturing, life science investment consulting, and metrology services. PSC Biotech Corporation has six unique divisions within the parent company...
Cytek Biosciences develops cell-analysis solutions for biomedical researchers, pharmaceutical companies, contract research organizations, and academic institutions. Its platform centers on patented Full Spectrum Profiling technology and includes flow cytometry instruments and cell sorters, imaging systems, reagents, software, and services. By analyzing the full spectrum of fluorescent signals, these tools enable sensitive, high-content cellular analysis and help scientists obtain deeper biological...
AB Enzymes is an industrial biotech company specialized in enzymes and their applications. The company is part of Associated British Foods and represented worldwide. Our offices are located in Brazil, China Germany, Finland, Singapore and USA. Our products range from food grade enzymes for baking and beverages, grains and vegetable oil seeds processing, to enzymes for animal feed and technical applications:...
About the Agency for Science, Technology and Research (A*STAR) The Agency for Science, Technology and Research (A*STAR) is Singapore's lead public sector agency that spearheads economic oriented research to advance scientific discovery and develop innovative technology. Through open innovation, we collaborate with our partners in both the public and private sectors to benefit society. As a Science and Technology Organisation, A*STAR...
A*STAR - Agency for Science, Technology and Research's Top Stability & Growth Strengths
Investor Backing & Capital Strength: Multi‑year national R&D allocations and top‑ups (RIE2025, RIE2030 S$37B, S$1B AI plan) and new earmarks (S$800M semiconductor flagship, S$500M biomedical refresh, NSTIC budgets) provide substantial funding capacity. These commitments underpin expansions in semiconductors, biomedicine, AI, and decarbonisation.
Strategic Partnerships: Deepening joint labs and collaborations with global and local industry (e.g., Rolls‑Royce–SAESL, Applied Materials at ARTC, Flagship Pioneering up to SGD100M, Labcorp facility) signal strong co‑development pipelines. Fresh bilateral calls and ecosystem partners committing capital reinforce translation momentum.
Future-Ready Strategy: Mission‑oriented expansions into semiconductors, AI, nucleic‑acid therapeutics, and sustainability, coupled with platforms like NSTIC and the mRNA BioFoundry, position the agency for emerging national priorities. Relocation and clustering of institutes (e.g., Jurong Innovation District; Biopolis refresh) support faster lab‑to‑market translation.
Our goal is to enable the analysis of anything, anywhere, by anyone. We have developed the world’s first and only nanopore DNA and RNA sequencing platform. It’s a new generation of sequencing technology — the only one to offer: scalability to portable or ultra-high throughput formats, real-time data delivery, and the ability to elucidate rich biological data. We are aiming to disrupt...
Oxford Nanopore Technologies's Top Stability & Growth Strengths
Strong Revenue Growth: Recent results show a meaningful step‑up in 2025 revenue with double‑digit year‑over‑year growth and guidance pointing to continued double‑digit expansion into 2026. Feedback suggests performance was slightly ahead of prior guidance and supported by broad‑based demand across regions and customer segments.
Strong Market Position & Advantage: ONT is described as a clear leader in nanopore sequencing and a co‑leader in long‑reads, differentiated by portability, real‑time analysis, ultra‑long reads, and native DNA/RNA methylation detection. Flagship datasets and assemblies reinforce this positioning.
Market Expansion: Updates highlight accelerating adoption beyond academia into clinical, applied industrial and biopharma use cases, alongside growing high‑throughput deployments on PromethION. Feedback suggests growth was evident across major geographies and end‑markets with notable momentum in regulated and applied settings.
Established in 2001, Avalere Health is a purposefully built commercialization partner for the biopharmaceutical, medical technology, and wellness industries. Our team of 1,500+ experts combine their knowledge and expertise across our core disciplines—Consulting; Medical; Policy; Value, Evidence, and Access; Marketing; and Digital Experience Technology—to create the connections that make better health happen. We partner with our clients to navigate the...
Avalere Health's Top Stability & Growth Strengths
Resilient & Sustainable Growth: Revenue expanded in consecutive years, with double‑digit growth in 2023 followed by continued albeit slower growth in 2024. Trade coverage frames 2024 as a cooling market overall, suggesting the company’s trajectory reflects resilience amid a softer cycle.
Strong Market Position & Advantage: Industry rankings place the firm consistently in the MM+M Agency 100 top 20 in 2024–2025. External awards and frequent policy visibility reinforce stature in core North American healthcare‑agency and U.S. policy/access segments.
Future-Ready Strategy: Leadership additions, a unifying rebrand, and integration of advisory, medical, access, and marketing indicate a connected commercialization model. New offerings, AI/data‑driven tools, partnerships, and the “Every Patient Possible” mission signal preparation for evolving client needs.
Edmund Optics has been a leading supplier of precision optics and optical components since 1942, designing and manufacturing a wide array of multi-element optical lenses, lens coatings, imaging systems, and optomechanical equipment. Led by a staff of skilled optical engineers and scientists, Edmund Optics is application focused and pursues new ways to implement optical technology, enabling advancements in industrial metrology,...
Sumitomo Electric Industries, Ltd. is a global technology and manufacturing company founded in Osaka in 1897. Its diversified business spans energy and environment, infocommunications, automotive, electronics, and industrial materials. The company supports people’s daily lives and industries through these five segments, serving customers worldwide via a network of around 400 group companies in 40 countries and a workforce exceeding 280,000...
Umami Bioworks is a marine biotechnology company developing cultivated seafood and other marine-derived biosolutions. Its AI-driven ALKEMYST platform combines genomics, stem cell biology, machine learning, and automation to enable scalable, traceable, cruelty-free production. The company licenses modular systems to manufacturing partners and supports applications in seafood, cosmetics, and nutrition, aiming to reduce overfishing and ecosystem strain while improving sustainable food...
10,000 people, one global focus - enhancing the health and well-being of pets, people, and livestock. We are passionate about what we do at IDEXX – and why wouldn’t we be? When you’re working to raise the standard of care for pets, make drinking water safe for billions and keep our livestock population around the globe healthy and free of...
IDEXX's Top Stability & Growth Strengths
Strong Market Position & Advantage: Market leadership in companion-animal diagnostics, reference labs, and veterinary software is repeatedly emphasized, underpinned by an integrated, closed-loop ecosystem that raises switching costs. Feedback suggests this position is reinforced by a broad global footprint and a large installed base of analyzers and labs.
Strong Revenue Growth: Revenue and earnings are described as steadily increasing, with recent quarters surpassing expectations and prompting raised full-year guidance. Company updates point to continued momentum across core segments.
Customer Loyalty & Retention: Bundled point-of-care equipment, consumables, reference-lab services, and practice software create sticky, recurring relationships and high utilization. The ‘razor/razorblade’ model supports repeat purchasing and long-term engagement with clinics.
Mouser Electronics is a worldwide leading authorized distributor of semiconductors and electronic components from over 1,100 manufacturer brands. We specialize in the rapid introduction of new products and technologies for design engineers and buyers. Our extensive product offering includes semiconductors, interconnects, passives, and electromechanical components. In 2007, Mouser became a part of the Warren Buffett Berkshire Hathaway family of companies. Today,...
Mouser Electronics's Top Stability & Growth Strengths
Strong Market Position & Advantage: Industry accounts position Mouser as a leader among authorized, high‑service distributors, with frequent “Distributor of the Year” awards and consistent inclusion on top distributor rankings. Its authorized model, NPI emphasis, and large automated Texas distribution center bolster competitive differentiation.
Product Line Growth: The line card expanded with 63 new manufacturers in 2025 and over 40,000 new parts, adding to a catalog of more than 6.8 million products from 1,200+ brands. This continued NPI‑led breadth supports design engineers and small‑to‑mid volume buyers.
Investor Backing & Capital Strength: As part of TTI within Berkshire Hathaway, the company benefits from financial stability and group scale. Parent disclosures highlight a 2025 rebound at TTI and ongoing investments in large‑scale warehouse automation and footprint expansion.
We’re TD SYNNEX (NYSE: SNX), a leading distributor and solutions aggregator for the IT ecosystem. We’re 22,000 of the IT industry’s best and brightest, who share an unwavering passion for bringing compelling technology products, services and solutions to the world. We’re an innovative partner that helps our customers maximize the value of IT investments, demonstrate business outcomes and unlock growth opportunities. At...
TD SYNNEX's Top Stability & Growth Strengths
Strong Market Position & Advantage: Independent channel analysts and repeated vendor awards place the company at or near the top globally, with 2024 gross billings around $80B and leadership versus Ingram Micro and Arrow. Global reach across 100+ countries and extensive vendor relationships underscores durable ecosystem influence.
Strong Revenue Growth: Recent quarters show revenue up 9.7% year over year in Q4 FY2025 and full-year FY2025 up roughly 6.9%, with non‑GAAP gross billings up 14.7% and records set for billings and earnings. Near‑term guidance for Q1 FY2026 indicates continued year‑over‑year growth if executed.
Healthy Cash Flow: Q4 FY2025 generated about $1.4B in free cash flow alongside strong operating cash flow. The company raised its dividend and continued buybacks, reflecting increased cash returns as performance accelerated late in FY2025.
Rakuten Medical, Inc. is a global clinical stage biotechnology company developing and commercializing precision, cell-targeting investigational therapies on its AlluminoxTM platform, which, in pre-clinical studies have been shown to induce rapid and selective cell killing and tumor necrosis. Outside of Japan, Alluminox therapies have not yet been approved as safe or effective by any regulatory authority. The company’s first drug...
ImmunoScape is a pre-clinical biotechnology company focused on the discovery and development of next-generation TCR cell therapies in the field of oncology. The company's proprietary Deep Immunomics technology platform enables highly sensitive, large-scale mining and immune profiling of T cells in cancer patient samples to identify novel, therapeutically relevant TCRs across multiple types of solid tumors. ImmunoScape has multiple discovery...
We are a digital-first, life sciences commercialization company. We help biopharmaceutical, emerging biotech and medical device companies develop products, get them to the market, and grow their impact through the life cycle in a more effective, efficient, and modern way. We bring together healthcare domain expertise, fit-for-purpose technology, and an agile operating model to provide a diverse range of solutions....
Indegene's Top Stability & Growth Strengths
Strong Market Position & Advantage: Independent analyst assessments place the company in leadership cohorts for life sciences commercial AI/analytics and digital services for commercial operations, indicating defensible positioning in its specialization. The company is also described as a best-fit provider for digital commercialization, omnichannel activation, content operations at scale, and AI-driven commercial analytics, reinforcing category leadership within that lane.
Strong Revenue Growth: Revenue shows clear acceleration into FY26, including a strong year-over-year increase in the latest reported quarter and a positive exit rate from prior quarters as deal wins converted. Full-year FY25 results also show year-over-year growth alongside continued profitability, supporting an upward growth trajectory.
Product Line Growth: Capability expansion is evidenced by recent acquisitions intended to deepen data-driven omnichannel, media offerings, and consulting/transformation coverage, broadening the commercialization toolkit. Ongoing scaling post-IPO is also framed as broadening capabilities beyond prior scope within its core focus areas.
